In short
mTOR (mechanistic target of rapamycin) is a protein kinase that senses nutrient and energy availability and, when active, drives cell growth and protein synthesis while suppressing autophagy.
mTOR sits at the center of two protein complexes, mTORC1 and mTORC2, which integrate signals from amino acids, glucose, growth factors, and cellular energy status. When nutrients and growth signals are abundant, mTORC1 activity promotes protein synthesis, cell growth, and proliferation — appropriate during development or after a meal, but chronically elevated mTOR signaling is one of the most consistently studied drivers in aging biology because it also suppresses autophagy, the cell's damage-clearance system.
The pathway is named for rapamycin, a compound discovered in soil bacteria on Easter Island (Rapa Nui) that binds and inhibits mTORC1. In laboratory animals, genetic or pharmacological reduction of mTOR signaling — including with rapamycin — is one of the most reproducible ways to extend lifespan across species from yeast to mice, including in the NIA-run Interventions Testing Program, which has repeatedly replicated a lifespan extension effect in genetically diverse mice.
In humans, mTOR inhibition is used clinically at immunosuppressive doses (organ transplant rejection prevention) and at lower doses in some longevity clinics off-label, but no human trial has shown that mTOR inhibition extends human lifespan — that evidence exists only in animal models. Human data so far covers surrogate markers like immune response to vaccination in older adults, not survival.
Worth remembering
- Nutrient-sensing kinase that promotes growth and suppresses autophagy when active.
- Rapamycin inhibits mTORC1 and reliably extends lifespan in multiple animal species.
- No human trial has shown mTOR inhibition extends human lifespan.
Where this shows up on the site
Frequently asked questions
Is mTOR always bad?
No. mTOR signaling is essential for growth, wound healing, and muscle protein synthesis after exercise. The aging-biology concern is with chronically elevated mTOR activity over decades, not the pathway's normal function.